Pacira Announces FDA Approval Of Expanded EXPAREL Label To Include Two Additional Nerve Block Indications
Portfolio Pulse from Benzinga Newsdesk
Pacira Pharmaceuticals has announced that the FDA has approved the expanded label of its product, EXPAREL, to include two additional nerve block indications. This will significantly extend its reach within more than 3 million lower extremity procedures.
November 10, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA approval of the expanded label for Pacira's EXPAREL is likely to increase the product's market reach, potentially boosting the company's revenues.
The FDA approval of the expanded label for EXPAREL allows the product to be used in more procedures, potentially increasing its market share and boosting Pacira's revenues. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100